Atlas Trials

Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

Clinical trial NCT05212454 · RECRUITING

Trial details

NCT number
NCT05212454
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Breast CancerChemotherapy Effect
Start date
2023-03-15
Primary completion
2025-12-01
Enrollment
400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.